VANCOUVER, British Columbia, Oct. 5, 2018 /PRNewswire/ –Terveystekniikka Oy, a strategic partner of WAT Medical Enterprise Ltd. (WAT Med), will participate in “I love me 2018”, the biggest health expo of Finland held from October 19-21, 2018. HeadaTerm and

WAT Medical’s innovative technology to treat all primary headaches, HeadaTerm, received its FDA clearance in September, 2018. This product, already approved by CE, HC, and now FDA, has been distributed

On August 20, 2018, Benny, CEO of B. Medical, visited WAT Med. Both parties held an in-depth discussion of the cooperation details concerning the strategic layout of Israeli market and

September 25 @ 8:00 AM – 9:30 AM You are invited to attend LifeSciences BC’s 2018 Annual General Meeting. The meeting will review the past fiscal year and preview plans

  For more information, please visit: www.amazon.com

Shortly after WAT Medical’s leading product to treat nausea-induced vomiting, EmeTerm, received its FDA clearance earlier in April, it has now also received official clearance from Health Canada. Health Canada

Vancouver BC – May 14, 2018 – WAT Medical’s leading product to treat nausea-induced vomiting, EmeTerm, has received its FDA clearance earlier in April. Now ready to officially enter the U.S.

Our future is being shaped by technology that’s evolving faster than we ever imagined. From AI machine learning to virtual and augmented reality, technology is revolutionizing every part of our

After MEDICA 2017, WAT Med has engaged into a busy and fulfilling work. With the emails receiving from all over the world and phone calls coming in all the day,

WAT Med will take part in the world’s leading trade fair for the medical industry, MEDICA in Dusseldorf from 13 – 16 November 2017. WAT Med is a company that develops safe, effective, and